Key facts: Allarity Therapeutics reports $7.9M Q3 loss; R&D expenses rise
I'm PortAI, I can summarize articles.
Allarity Therapeutics, Inc. posted a net loss of $7.9 million in Q3 2025, down $9.2 million from Q3 2024, due to lower operating costs and higher foreign exchange gains.1In the third quarter of 2025, Allarity Therapeutics, Inc. (ALLR) reported research and development expenses of $1.2 million, up from $1.0 million in the same quarter of 2024.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments